Apogee Earnings Reports

Apogee Therapeutics reported full year 2024 financial results, highlighting the accelerated execution of the Phase 2 APEX clinical trial for APG777 and the positive interim Phase 1 results for APG990. The company's cash, cash equivalents, and marketable securities totaled $731.1 million, providing a runway into Q1 2028.

Apogee Therapeutics reported its Q3 2024 financial results, highlighting continued execution across all programs, including positive results from the APG777 Phase 1 trial. The company is on track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024, and interim Phase 1 data for APG990 in 1H 2025. Apogee had $753.8 million in cash, cash equivalents, and marketable securities, providing runway into 2028.

Apogee Therapeutics reported pipeline highlights and second quarter financial results, with a focus on advancing its pipeline, including APG777, APG808, and APG990, and adding APG333 to its portfolio. The company plans combination studies and has a cash runway into 2028.

Apogee Therapeutics reported its first quarter financial results, highlighting the initiation of a Phase 2 clinical trial for APG777, dosing of the first participant in the Phase 1 trial of APG808, and nomination of a development candidate for APG990. The company's cash runway extends into 2028, supported by $816 million in cash, cash equivalents and marketable securities.

Apogee Therapeutics reported a net loss of $31.7 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $395.5 million as of December 31, 2023, which is expected to fund operations into 4Q 2026.